A. Soto

发表

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

R. Salazar, J. Soria, J. Armand, 2012, Investigational New Drugs.

Phase I (3 hour infusion every 3 weeks) escalating dose study of intravenous ES-285 in patients with advanced malignant solid tumors

R. Salazar, J. Soria, J. Armand, 2007 .

179 POSTER Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors or lymphoma

R. Plummer, J. Soria, C. Massard, 2008 .

Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer

S. Fudio, I. Trocóniz, C. Fernández-Teruel, 2018, Clinical Pharmacokinetics.

A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study.

P. Kearns, B. Geoerger, G. Vassal, 2012, European journal of cancer.

Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS).

J. Blay, G. Demetri, A. Italiano, 2013 .

Lurbinectedin (PM01183), an active compound in platinum-resistant/refractory ovarian cancer (PRROC) patients: Results of a two-stage, controlled phase II study.

I. Ray-Coquard, A. Nieto, C. Kahatt, 2014 .

Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations

R. Schilsky, M. Ratain, S. Undevia, 2008 .